Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution

HIV Medicine

Volumn 10, Issue 5, 2009, Pages 290-301

  Williams, Paige L ^a   Wu, J W ^a   Cohn, S E ^b   Koletar, S L ^c   McCutchan, J A ^d   Murphy, R L ^e   Currier, J S ^f   Putnam, Bev ^g   Ray, Graham ^g   Kessler, Harold ^h   Adeyemi, Oluwatoyin ^e   Cahill, Susan ⁱ   Hoffman, Julie ⁱ   Salata, Robert ^j   Galloway, Patricia ^j   Payne, Mary M ^k   Lawrence, Jody ^k   Reid, Jane ^b   O'Hara, Tammy ^b   Norris, Jane ^l   Valle, Sandra ^l   Squires, Kathleen E ^m   Watson, Kathy ^c   Mills, Charlotte ^c   Gaca, Charlene ⁿ   Cooley, Timothy ⁿ   Witt, Mallory ^f   Shaik, Sadia ^f   Forcht, Janet ^o   Gonzales, Charles ^o   Glesby, Marshall ^p   Hughes, Valery ^p   Storey, Sheryl ^q   Schouten, Jeff ^q   Balfour Jr , Henry H ^r,s   Fietzer, Christine ^r,s   Gunthel, Clifford ^t   Patrick, Ericka ^t   O'Brien, William A ^u   Casey, Gerianne ^u   Rodriguez, Mark ^v   Kessels, Lisa ^v   Feinberg, Judith ^w   Powell, Tammy ^w   Goldman, Mitchell ^x   Zwickl, Beth ^x   Riddle, Joan ^y   MacDougall, Pualette ^y   van der Horst, Charles ^z,aa   Ragan, David ^z,aa   Chusid, Ellen ^ab   Weiss, Walter ^ab   Mildvan, Donna ^ac   McNeil, John ^ad   MacGregor, Rob Roy ^ae   Maffei, Kathryn ^ae   Wiggins, Ilene ^af   Worrell Thorne, Robin ^af   Clark, Rebecca A ^ag   Steinberg, James Paul ^t   more..

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

^k SAN FRANCISCO GENERAL HOSPITAL   (United States)

^l STANFORD UNIVERSITY   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ HARVARD UNIVERSITY   (United States)

^o NEW YORK UNIVERSITY   (United States)

^p Ohio State University ^*  (United States)

^q UNIVERSITY OF WASHINGTON   (United States)

^r UNIVERSITY OF MINNESOTA   (United States)

^s UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^t EMORY UNIVERSITY   (United States)

^u UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^v WASHINGTON UNIVERSITY   (United States)

^w UNIVERSITY OF CINCINNATI   (United States)

^x INDIANA UNIVERSITY   (United States)

^y DUKE UNIVERSITY MEDICAL CENTER   (United States)

^z UNIVERSITY OF NORTH CAROLINA   (United States)

^aa UNIVERSITY OF HAWAII   (United States)

^ab Mt Sinai Medical Center   (United States)

^ac NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^ad HOWARD UNIVERSITY   (United States)

^ae UNIVERSITY OF PENNSYLVANIA   (United States)

^af JOHNS HOPKINS UNIVERSITY   (United States)

^ag TULANE UNIVERSITY   (United States)

more..

Author keywords

Cardiovascular disease; Cholesterol; HAART; Immune reconstitution; Metabolic syndrome

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LIPID; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DRUG CHOICE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; ANTILIPEMIC AGENTS; BENZOXAZINES; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TREATMENT OUTCOME;

EID: 65449175642     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00685.x     Document Type: Article

References (41)

1. Maggi P, Serio G, Epifani G et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14: F123-F128.
2. Depairon M, Chessex S, Sudre P et al. for the Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals: Focus on protease inhibitor therapy. AIDS 2001; 15: 329-334.
3. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus and lipodystrophy. Clin Inf Dis 2001; 32: 130-139.
4. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving protease inhibitor therapy. AIDS 1998; 12: F51-F58.
5. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
6. Nguyen A, Calmy A, Schiffer V et al. for the Swiss HIV Cohort Study. Lipodystrophy and weight changes: Data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008; 9: 142-150.
7. Friis-Møller N, Weber R, Reiss P et al. for the DAD study group. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy: Results from the DAD Study. AIDS 2003; 17: 1179-1193.
8. Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immun Defic Syndr 2000; 23: 35-43.
9. Fontas E, van Leth F, Sabin CA et al. for the D:A:D Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different drugs associated with different lipid profiles? J Inf Dis 2004; 189: 1056-1074.
10. Young J, Weber R, Rickenbach M et al. Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV Cohort Study. Antivir Ther 2005; 20: 585-591.
11. Shlay JC, Bartsch G, Peng G et al. Long-term body composition and metabolic changes in antiretroviral naïve persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor- or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007; 44: 506-517.
12. Chen D, Anoop M, Garg A. Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87: 4845-4856.
13. Palacios R, Santos J, García A et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naïve patients. HIV Med 2006; 7: 10-15.
14. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-2982.
15. Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: The price of success. JAMA 2006; 296: 844-854.
16. El-Sadr WM, Mullin CM, Carr A et al. Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naïve cohort. HIV Med 2005; 6: 114-121.
17. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700-705.
18. Purnell JQ, Zambon A, Knopp RH et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 51-57.
19. Bausserman LL, Tashima KT, DiSpigno M, Maceroni D, Carpenter CC. Racial differences in serum lipids in HIV-positive women treated with protease inhibitor regimens. HIV Clin Trials 2004; 5: 399-405.
20. Montes ML, Pulido F, Barros C et al. Lipid disorders in antiretroviral-naïve patients treated with lopinavir/ ritonavir-based HAART: Frequency, characterization and risk factors. J Antimicrob Chemother 2005; 55: 800-804.
21. Levy AR, McCandless L, Harrigan PR et al. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis 2005; 4: 4.
22. Negredo E, Ribalta J, Ferré R et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004; 18: 819-821.
23. Negredo E, Molto J, Burger D et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA Study). J Acquir Immune Defic Syndr 2005; 38: 47-52.
24. van der Valk M, Kastelein JJ, Murphy RL et al. for the Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1-infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-2414.
25. van Leth F, Phanuphak P, Stroes E et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1. PLoS Med 2004; 1: E19.
26. Johnson M, Grinsztejn B, Rodriguez C et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virologic failures. AIDS 2005; 19: 685-694.
27. Kumar PN, Rodriguez-French A, Thompson MA et al. for the ESS40002 Study Team. A prospective, 96-week study of the impact of trizivir, combivir/ nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters, and efficacy in antiretroviral-naïve patients: Effect of sex and ethnicity. HIV Med 2006; 7: 85-98.
28. Friis-Moller N, Reiss P, Sabin CA et al. for the DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
29. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D for the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
30. Henry K, Melroe H, Huebsch J et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 8: 1328.
31. Friedl AC, Attenhofer Jost CH, Schalcher C et al. Acceleration of confirmed coronary artery disease among patients on potent antiretroviral therapy. AIDS 2000; 14: 2790-2792.
32. Klein D, Hurley LB, Quesenberry CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
33. Holmberg SD, Moorman AC, Williamson JM et al. for the HIV Outpatient Study. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-1748.
34. Currier JS, Williams PL, Koletar SL et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4 cell count. Ann Intern Med 2000; 133: 493-503.
35. National Cholesterol Education Program (NCEP): Third report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No. 01-3670.
36. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer, 2000.
37. Koletar SL, Williams PL, Wu J et al. for the ACTG 362 Study Team. Long-term follow-up of HIV-infected individuals who have significant CD4 increases with antiretroviral therapy. Clin Inf Dis 2004; 39: 1500-1506.
38. Hadigan C, Meigs JB, Wilson PWF et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Inf Dis 2003; 36: 909-916.
39. Sabin CA, d'Arminio Monforte A, Friis Møller N et al. for the Data Collection of Adverse Events of Anti-HIV Drugs Study Group. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Inf Dis 2008; 46: 1101-1110.
40. Currier JS, Scherzer R, Bacchetti P et al. for the FRAM Study Investigators. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 2008; 48: 35-43.
41. Friis-Moller N, Thiebaut R, Reiss P for the D:A:D Study Group. Predicting the risk of coronary heart disease in HIV-infected patients. The D:A:D risk equation. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 2007 [Abstract 808].